Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8239825 | PMC |
| http://dx.doi.org/10.1002/cpt.2288 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
We investigated the steady-state pharmacokinetics of generic abacavir (ABC)/lamivudine (3TC) dispersible tablets (DTs) in young children living with HIV aged 3 months to <7 years, weighing 6 to <20 kg. Twenty-eight Thai children were enrolled and received ABC/3TC-DT plus pediatric dolutegravir-DT once daily. ABC/3TC was administered using WHO weight band (WB) doses: 180/90 mg, 240/120 mg and 300/150 mg for children weighing 6 to <10 kg (WB 1, n = 7), 10 to <14 kg (WB2, n = 9) and 14 to <20 kg (WB3, n = 12), respectively.
View Article and Find Full Text PDFTherapeutic Drug Monitoring of High-dose Sulbactam in Pediatric Patients: Preliminary Data From a Prospective Observational Pharmacokinetic Study.
Pediatr Infect Dis J
October 2024
From the Division of Infectious Diseases, Department of Pediatrics, Faculty of Medicine.
Background: Rates of carbapenem-resistant Acinetobacter baumannii are rising in Thailand. Although high-dose (HD) sulbactam is recommended for treating carbapenem-resistant A. baumannii infections, data on plasma sulbactam concentrations in children are limited.
View Article and Find Full Text PDFArticle Synopsis
- The text discusses the importance of forecasting future health issues in the USA for effective planning and public awareness regarding disease and injury burdens.
- It describes the methodology for predicting life expectancy, cause-specific mortality, and disability-adjusted life-years (DALYs) from 2022 to 2050 using the Global Burden of Diseases framework.
- The forecasting includes various scenarios to assess the potential impacts of health risks and improvements across the country, focusing on demographic trends and health-related risk factors.
Pulmonary embolism after SARS-CoV-2 vaccination.
Vaccine X
December 2024
The Swedish Medical Products Agency, Uppsala, Sweden.
Article Synopsis
- The study aimed to investigate the risk of pulmonary embolism (PE) after COVID-19 vaccination in the Swedish population aged 18 to 84 during the vaccination campaign from December 2020 to December 2022.
- Using a cohort study approach, researchers analyzed data from around 6.1 million vaccinated individuals and identified 12,456 cases of PE, finding slight increases in risk specifically after the first doses of two out of three vaccines.
- Overall, the study concluded that no strong associations existed between COVID-19 vaccinations and PE, suggesting that any increased risk might be due to factors like prioritizing vulnerable populations rather than the vaccines themselves.
Autoantibodies to protein S may explain rare cases of coagulopathy following COVID-19 vaccination.
Sci Rep
October 2024
Science for Life Laboratory, Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden.
While Coronavirus disease 2019 (COVID-19) vaccines have proven to be both effective and generally safe, rare but severe adverse events following immunization (AEFIs) are described. Autoantibodies to platelet factor-4 are associated with catastrophic thrombotic AEFIs, but comprehensive investigations of other autoantibodies are lacking. We aimed to detect and describe autoantibodies targeting coagulation-related proteins in a population-wide cohort (SWEDEGENE) including AEFIs attributed to COVID-19 vaccines in Sweden.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!